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Background. Combination antiretroviral therapy (cART) generally suppresses the replication of the human
immunodeficiency virus type 1 (HIV-1) but does not cure the infection, because proviruses persist in stable latent
reservoirs. It has been proposed that low-level proviral reservoirs might predict longer virologic control after dis-
continuation of treatment. Our objective was to evaluate the impact of very early initiation of cART and temporary
treatment interruption on the size of the latent HIV-1 reservoir in vertically infected children.
Methods. This retrospective study included 23 perinatally HIV-1-infected children who initiated very early
treatment within 12 weeks after birth (n = 14), or early treatment between week 12 and 1 year (n = 9). We measured
the proviral reservoir (CD4+ T-cell–associated HIV-1 DNA) in blood samples collected beyond the first year of
sustained virologic suppression.
Results. There is a strong positive correlation between the time to initiation of cART and the size of the proviral
reservoir. Children who initiated cART within the first 12 weeks of life showed a proviral reservoir 6-fold smaller
than children initiating cART beyond this time (P < .01). Rapid virologic control after initiation of cART also limits
the size of the viral reservoir. However, patients who underwent transient treatment interruptions showed a dramatic
increase in the size of the viral reservoir after discontinuation.
Conclusions. Initiation of cART during the first 12 weeks of life in perinatally HIV-1-infected children limits the
size of the viral reservoir. Treatment interruptions should be undertaken with caution, as they might lead to fast and
irreversible replenishment of the viral reservoir.
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Perinatal infection by human immunodeficiency virus
type 1 (HIV-1) can be diagnosed during the first days
of life in newborns infected in utero or 2–6 weeks after
delivery in infants infected during delivery. Compared
with older children and adults [1], acute infection in ba-
bies is characterized by a sustained high-level plasma
viral load (pVL) in the initial years of infection [2, 3]
and a high risk of rapid progression to AIDS and
death [4]. The rapid reduction of peak pVL that is char-
acteristic of acute HIV-1 infection in adults occurs very
slowly during the first months of an infant’s life. These
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age-associated disparities in the viral kinetics of HIV-1 and the
clinical outcome of HIV infection are most likely attributable to
developmental differences in the neonatal immune system [5, 6].
AIDS-related mortality in children has decreased significantly
with the wide availability of combination antiretroviral therapy
(cART). Initially, cART was strongly recommended only in in-
fants with HIV-related symptoms [7]. However, during recent
years, multiple studies have suggested the benefit of starting
early cART in all HIV-1-infected infants [8–11].Therefore, inter-
national guidelines are now recommending initiation of cART in
all HIV-1-infected infants aged less than 1 year regardless of clin-
ical and immunological conditions [12, 13].
Some HIV-1-infected infants who initiate cART soon after
birth do not display HIV-1-specific antibodies or cellular re-
sponses, thus indicating early control of viral replication [14,
15]. Nevertheless, HIV-1 infection quickly establishes latent
reservoirs, mainly in resting memory CD4+ T cells. Although
the memory T-cell population in peripheral blood is small in
newborns [16], only to develop later in childhood [17], recent
findings demonstrate the presence of HIV-1-susceptible memory
CD4+ T cells in the gut of newborns [18]. The limitations on es-
tablishment of reservoirs facilitated by early cART could play a
critical role in achieving natural control of viral replication
upon discontinuation of cART, which could be defined as “func-
tional cure” [17, 19–22]. On the other hand, viral reservoirs could
provide a persistent source of recrudescent viraemia despite tem-
porary remission of HIV-1 infection after withdrawal of treat-
ment [23], as observed in the so-called Mississippi baby [24].
Therefore, in order to design interventions aimed at achieving
functional cure in this population, it is important to understand
how very early initiation of cART can affect persistence of HIV-1
in older children with successfully suppressed viraemia.
We retrospectively studied a cohort of perinatally HIV-1-
infected children who initiated cART within the first year of life.
We compared initiation of cART within the first 12 weeks of life
with initiation at a later date to assess the potential limitation of
establishment of viral reservoirs in the long-term. Our data show
that the extent of the latent infection can be limited by adminis-
tration of optimal cART shortly after birth, which leads to rapid
viral suppression. Some of the infants included in this cohort had
undergone treatment interruptions. The analysis of the effects of
interruptions on the dynamics of viral reservoir indicates that very
low reservoir size is not a prognostic marker of long-lasting HIV
remission and that reservoir replenishment driven by viral re-
bound may be fast and irreversible even in these cases.
MATERIALS AND METHODS
Study Participants
The study was based on 139 children with vertically transmitted
infection from the Paediatric Spanish AIDS Research Network
Cohort (coRISpe). Only samples from those children who ini-
tiated cART within the first year of life were included. The anal-
ysis was finally based on samples from 23 children who had
maintained viral suppression (≤200 copies/mL) for at least 1
year before sampling. When possible, we selected samples that
had been collected at multiple time points. Cryopreserved plas-
ma and peripheral blood mononuclear cells (PBMC) and asso-
ciated clinical data were provided by the Spanish HIV HGM
BioBank [25] and by coRISpe [26]. Clinical classification of
AIDS-defining events and immunologic categories were based
on international guidelines [27]. The ethics committee of Hos-
pital Gregorio Marañón in Madrid approved the study.
Quantification of Proviral HIV-1 DNA
To evaluate the size of the proviral reservoir, CD4+ T cells were
purified from PBMC by negative immunomagnetic separation
(CD4+ T Cell Isolation Kit; Miltenyi Biotech), and lysed extracts
were used to measure cell-associated total HIV-1 DNA by droplet
digital polymerase chain reaction (ddPCR) with 5′LTR or Gag
primers and probes, depending on the efficiency of detection in
each patient. The 2 primer-probe sets have been previously
assessed to be comparable in terms of efficiency and sensitivity
by ddPCR on a plasmid containing the IIIB reference HIV-1 se-
quence (standard 2LTR-CCR5 plasmid, kindly provided by
M. Stevenson). However, mismatches or deletions in the viral se-
quences can prevent from efficient amplification in some patient
samples. For that reason all samples were measured in parallel
using the 2 primer-probe sets to ensure efficient and reliable pro-
viral absolute quantification. The RPP30 cellular gene was quan-
tified in parallel to normalize sample input. All primers and FAM/
HEX-ZEN-Iowa BlackFQ dual-labeled double-quenched probes
were purchased from Integrated DNA Technologies [28, 29].
Serological Assessment
The Inno-Lia HIV I/II Score assay (Innogenetics, Ghent, Bel-
gium) was run as previously described [30] to evaluate humoral
responses in plasma samples (taken simultaneously with stored
PBMCs). The results of antibody testing for HIV-1 antigens
gp120, gp41, p31, p24, and p17 were analyzed and classified
as positive if at least 2 lines had a rating ≥1+, and both were
envelope lines or at least 1 was an envelope antigen and the
other p24. Other combinations were considered indeterminate.
Ultrasensitive Viral Load Test
Residual low-level viraemia was determined by ultracentrifuga-
tion of up to 7.5 mL of plasma at 170 000 i at 4°C for 30 min-
utes, followed by viral RNA extraction using the m2000sp
Abbot device. HIV-1 RNA copies were quantified in the Abbot
m2000rt instrument using the Abbott RealTime HIV-1 Assay
and laboratory-defined applications software from the instru-
ment. HIV-1 RNA copies in the low range were determined by
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means of a calibration curve set between 1000 and 10 copies/mL
(five points at 1/3 serial dilutions: 1000, 300, 100, 30, and 10 in
triplicate). The quantification method was validated in triplicate
with a positive control (prequantified standard HIV from the
World Health Organization) in the range of 128–0.5 copies/
mL (9 serial 1/2 dilutions). Similarly, the concentration protocol
was validated by running direct vs diluted ultracentrifuged pre-
quantified plasma samples, with viral load (VL) ranging from
400 to 10 HIV-1 RNA copies/mL.
Statistical Analysis
We compared numerical and categorical variables between
groups using the Mann–Whitney test and Fisher exact test,
respectively.
A multiple linear regression model was fitted to define the as-
sociation between HIV-1 DNA and previously selected clinical
variables. Selection was performed by means of a Spearman
pairwise correlation test to identify those parameters that were
significantly correlated with HIV-1 DNA and as independent as
possible between them. The final model—log10 (copies HIV-1
DNA/106 CD4+ T cells) = (Age at cART initiation) + (Time
to virologic control)—was derived using a bootstrapped Akaike
information criterion–based stepwise selection method (Sup-
plementary Figure 1).
Longitudinal changes within groups of children who discon-
tinued or did not discontinue cART and the comparison of the
mean change between groups (slope coefficient) were evaluated
using linear mixed models: log10 (copies HIV-1 DNA/10
6 CD4+
T cells) = intercept + group + timepoint + group*timepoint. A
statistically significant interaction term (group*timepoint)
identified significantly different slopes between the groups. To
perform these longitudinal analyses, timepoints were defined
according to the time since the first determination: 0.5–2
years, 2–2.5 years, 2.5–3 years, and more than 3 years. All anal-
ysis were performed using the R package [31].
RESULTS
The study population comprised 23 perinatally HIV-1-infected
children, who were grouped into 2 categories: those who initi-
ated cART very early (VET, 0–12 weeks, 14 patients) or early
(ET, 12–54 weeks, 9 patients). The first cART regimen consisted
of a backbone of 2 nucleoside reverse transcriptase inhibitors
(mostly lamivudine and zidovudine) plus either a nonnucleo-
side reverse transcriptase inhibitor (nevirapine) or a protease
inhibitor (nelfinavir or lopinavir/ritonavir). Clinical and demo-
graphic characteristics are summarized in Table 1. At sampling,
all patients responded effectively to cART and had been virolog-
ically suppressed (≤200 copies/mL) for more than 1 year (me-
dian time on suppression = 4.5 years [interquartile range (IQR):
3.3–6.9]). At sampling (median age = 8.0 years [IQR: 5.1–10.0]),
17 children were on a protease inhibitor–based regimen.
We first explored the potential association between proviral
reservoir size and the main clinical parameters. We found a
strong positive correlation between total HIV-1 DNA in
CD4+ T cells and the age of the children at initiation of cART
(P-value <.0001; Figure 1A). Indeed, children treated within the
first 12 weeks of life had a smaller reservoir than children treat-
ed later (P-value <.01; Figure 1B). A positive correlation was
also found between total HIV-1 DNA in CD4+ T cells and
the time needed to achieve viral suppression after initiation of
cART (P-value = .03; Figure 1C). However, we did not find stat-
istically significant differences when children were classified as
rapid controllers (≤1 year) or slow controllers (>1 year) (Fig-
ure 1D). A more accurate analysis, in which the main clinical
parameters were fitted into a mixed linear model, confirmed
that the most significant parameters contributing to proviral
reservoir size were age at initiation of cART (P-value = .002)
and time between initiation of cART and virologic control
(P-value = .04) (Supplementary Figure 1). The resulting model
predicts an increment of 0.1 log in the total HIV-1 DNA con-
tent of peripheral CD4+ T cells driven by each 1-month delay in
the initiation of cART (Figure 2A). Similarly, an equivalent in-
crement would result from each year of suboptimal treatment.
Since the samples were not evaluated at the same timepoints, we
ruled out the possibility that the total time under virologic con-
trol until sampling could affect the total amount of cell-
associated HIV-1 DNA (Supplementary Figure 2A and 2B).
Ultrasensitive viral load quantification was used to compare
pVL at the time of sampling (Table 1): residual low-level virae-
mia was detectable in 7 children (30%), 3 (21.4%) in the VET
group and 4 (43.4%) in the ET group, with no significant differ-
ences between groups, neither in the frequency of detection nor
in median levels.
HIV-1-specific antibody testing was performed to assess the
children’s serostatus. We analyzed the relationship between
HIV-1 serostatus and age at initiation of treatment, time to
virologic control and proviral reservoir size. As shown in Fig-
ure 2B, a higher proportion of VET children presented negative
or indeterminate results: seven of the 14 children in the VET
group (50%) vs only one of the 9 ET children (11.1%), probably
as a result of early and sustained control of viral replication
(Table 2 and Supplementary Table 1). However, this trend was
not statistically significant (Fisher exact test P-value = .09), and
no association was found between serological status and proviral
reservoir size (Mann–Whitney test P-value = .20).
The potential role of an extremely small proviral reservoir as
a correlate of protection against viral rebound after interruption
of treatment remains controversial. Thus, we studied the effect
of discontinuation on reservoir size by comparing the longitudi-
nal dynamics of the latent reservoir in three children who
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discontinued cART and nine children who continued cART. The
3 children who discontinued belonged to the VET group and had
a median of 25 HIV-1 copies per million CD4+ T cells (IQR: 15–
68). However, this value increased to 199 copies (IQR: 123–778)
after discontinuation despite virologic control for at least one year
after reinitiation of cART (Table 3). Even though only a few pa-
tients were evaluated, longitudinal analysis revealed a statistically
significant increase in the size of the proviral reservoir in this




Very Early (VET) Early (ET)
0–12 wk 12–54 wk
23 (100%) 14 (60.9%) 9 (39.1%)
Subject characteristics
Sex, No. (%)
Female 15 (65.2) 8 (57.1) 7 (77.8) .3998
HIV-1 subtype, No. (%)
B 19 (82.6) 11 (78.6) 8 (88.9) 1.0000
No B 3 (13) 2 (14.3) 1 (11.1)
Gestational age
Median [IQR], wk 38 [36–39] 38 [36–39] 39 [38–41] .1431
Received prophylaxis, No. (%)
Yes 11 (47.8) 8 (57.1) 3 (33.3) .4003
Zenith pVL
Median [IQR], log10 cp/mL 5.8 [5.3–6.2] 5.6 [5.1–6.2] 6 [5.7–6.1] .2560
Nadir CD4+ T-cell count
Median [IQR], cells/mm3 663 [405–1125] 665 [386–1232] 663 [418–1058] .9749
Median [IQR], % 26 [14–33] 31 [16–36] 15 [14–26] .1382
Parameters at cART initiation
Median age [IQR], wk 10 [6–28.4] 7.2 [2.8–9.6] 32.4 [27.3–35.6] <.0001
CDC category
N or A 16 (69.6) 13 (92.9) 3 (33.3) .0091
B 2 (8.7) 0 2 (22.2)
C 5 (21.7) 1 (7.1) 4 (44.4)
CD4+ T-cell count
Median [IQR], cells/mm3 1785 [1069–3120] 2733 [1455–3733] 1508 [932–1785] .0507
Median [IQR], % 43 [24–48] 44 [42–50] 24 [16–35] .0196
Immune category
1 14 (60.9) 12 (85.7) 2 (22.2) .0086
2 6 (26.1) 1 (7.1) 5 (55.6)
3 3 (13) 1 (7.1) 2 (22.2)
Initial cART regimen, No. (%)
With protease inhibitors 18 (78.3) 9 (64.3) 9 (100) .1157
Parameters at virologic control
Time since cART initiation
Median [IQR], yr 0.8 [0.5–4.2] 0.5 [0.4–3.8] 1.4 [0.7–5.3] .2433
Median age [IQR], yr 1.3 [0.5–4.5] 0.6 [0.5–3.9] 2 [1.3–6.3] .0725
Parameters at sampling
Median age [IQR], yr 8 [5.1–10] 7.6 [4.3–9.6] 9.1 [6–10.4] .3610
cART regimen, No. (%)
with protease inhibitors 17 (73.9) 9 (64.3) 8 (88.9) .3401
Time on cART
Median [IQR], yr 7.9 [4.7–9.8] 7.5 [4.2–9.5] 8.6 [5.4–9.9] .5495
Time under virologic control
Median [IQR], yr 4.5 [3.3–6.9] 5.2 [2.9–7.4] 4.1 [3.7–4.8] .8749





Very Early (VET) Early (ET)
0–12 wk 12–54 wk
23 (100%) 14 (60.9%) 9 (39.1%)
Ultrasensitive pVL, No. (%)
Undetectable, No. (%) 16 (69.6) 11 (78.6) 5 (55.6) .6244
Median [IQR] of detectable, cp/mL 10 [4.7–12] 10 [10–11] 5 [4–15] .6600
CD4+ T-cell count
Median [IQR], cells/mm3 1356 [1046–1668] 1258 [952–1649] 1416 [1179–1680] .4310
Median [IQR], % 40 [36–44] 41 [36–43] 38 [37–51] .7283
Virologic control was defined as 2 consecutive pVL determinations of <200 copies/mL after cART initiation. Values are shown as median [IQR] or number (%). The
clinical classification of AIDS-defining events and immunologic categories were based on international guidelines. Prophylaxis with zidovudine, lamivudine, and
nevirapine immediately followed by cART was considered as initiation of cART. Data were compared between infants initiating cART at less than 12 weeks of
age (VET) and infants initiating cART between 12 and 54 weeks of age (ET) using the Mann–Whitney test and Fisher exact test for numerical or categorical
variables, respectively.
Abbreviations: cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; ET, early treatment; HIV-1, human immunodeficiency
virus type 1; IQR, interquartile range; pVL, plasma viral load; VET, very early treatment.
Figure 1. Association between human immunodeficiency virus type 1 (HIV-1) DNA copies/106 CD4+ T cells and age at initiation of treatment (A and B) or
time to virologic control after initiation of treatment (C and D). Median (interquartile range) levels are shown. The non-parametric Spearman correlation
coefficient (ρ) and the associated 2-tailed P value (A and C) and 2-tailed P value of grouped comparisons (Mann–Whitney test) (B and D) are shown.
Abbreviations: ET, early treatment; VET, very early treatment.
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group (slope = 0.29; P = .0005), whereas no significant longitudi-
nal changes were found in individuals with complete adherence
to cART (slope = –0.02; P = .68) (Figure 3A). Evaluation of each
individual case revealed no correlation between serostatus or ini-
tial proviral reservoir size and the extent of reservoir replenish-
ment or time to viral rebound.
Of particular interest is the case of patient (Pt03), whose
plasma viraemia levels, CD4+ T-cell counts, and proviral
DNA are shown in Figure 3B. This patient initiated cART
with zidovudine, lamivudine, and nevirapine immediately
after birth and achieved viral suppression 6.5 months later.
At 2 years of age, his proviral reservoir size was extremely
low (3.8 total HIV-1 DNA copies/106 CD4+ T cells), and at
2.2 years of age, treatment was discontinued for 3 weeks
(Table 3 and Figure 3B). Unexpectedly, this brief treatment in-
terruption led to viral rebound within the first week followed
by a rapid increase in pVL up to 500 000 HIV-1 RNA copies/
mL. Once cART was restored, pVL decreased rapidly, but the
reservoir size increased approximately 50-fold and remained
so for the next 3 years.
Figure 2. Influence of age at initiation of treatment and time to virologic control after initiation of treatment on proviral reservoir size and humoral profiles.
A, Three-dimensional graph shows raw data (black circles) with the predicted multiple model (red plane). B, Bubble size represents human immunodeficiency
virus type 1 (HIV-1) reservoir size (HIV-1 DNA copies/106 CD4+ T cells). Measurements in infants who had fully seroconverted are in blue. Patients with
negative or indeterminate results in the Inno-Lia assay are indicated in light or dark orange, respectively. Abbreviations: cART, combination antiretroviral
therapy; ET, early treatment; VET, very early treatment.
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DISCUSSION
To date, the advantages of initiating cART within the first year
in perinatally infected newborns were thought to maximize the
potential benefits of limiting a latent reservoir size and enabling
reservoir decay, which could probably increase the duration of
remission and limit the capacity for reestablishment of viraemia
in patients whose treatment is discontinued [20, 32–34]. Our
study highlights the importance of very early initiation of
cART, if possible within the first 12 weeks of life, and the benefit
of optimal virologic control during the first years of life in order
to limit the size of the viral reservoir. However, our study also
casts doubt on the ability of a small viral reservoir to limit viral
rebound after discontinuation (as observed in the case of the
Mississippi baby).
In accordance with Persaud and colleagues [35], who high-
lighted the influence of age at virologic control on peripheral
blood HIV-1 reservoir size in perinatally infected adolescents,
our results for viral reservoir size in CD4+ T cells also correlate
significantly with age at virologic control (P-value <.005;
Supplementary Figure 3A), namely, a 4-fold increase in cell-
associated DNA in patients who achieved virologic control
with more than 1 year of age (Supplementary Figure 3B). How-
ever, these results are markedly affected by the fact that 8 out of 9
patients who achieved virologic control during the first year of
life started their cART before 12 weeks. We examined our find-
ings in greater depth by independently analyzing age at initiation
of cART and time to viral suppression and found that, although
both parameters were associated with reservoir size, the effect of
the age at initiation of treatment was stronger (Figure 1).
Our results show that the earlier cART is initiated, the small-
er the size of the proviral reservoir in peripheral CD4+ T cells in
HIV-infected children. This finding is in line with those of a re-
cent study that compared cell-associated HIV-1 DNA in perina-
tally infected infants initiating treatment before 12 weeks of age
with patients initiating treatment during adolescence [36].
Moreover, our findings are consistent with those of a study of
adult post-treatment controllers who initiated cART during
acute HIV-1 infection [19], indicating that early treatment
can prevent seeding of long-lived cellular reservoirs. Taken to-
gether, our results, which focus on a narrower time frame, clear-
ly show the importance of treating infants immediately after
birth to minimize seeding of long-lived cellular reservoirs.
The relevance of testing the HIV reservoir as a potential cor-
relate of viral control after discontinuation has been the subject
of intensive research in recent years, ever since the description




Sex Male Male Female
HIV-1 subtype B B B
Gestational age, wk 38 30 38
Received prophylaxis No Yes No
Zenith pVL, log10 cp/mL 4.0 5.0 6.5
Nadir CD4+ T-cell count
Cells/mm3 2410 1466 1305
% 36 32 46
Parameters at cART initiation
Age, wk 0.0 7.6 5.1
CDC category A A A
CD4+ T-cell count
Cells/mm3 ND 4133 2209
% 48.1 42 47
Immune category 1 1 1










Age, mo 6.2 22.7 3.9
Parameters of cART discontinuation
Serostatus before TD Positive Positive Negative
Duration of TD, wk 3 27 284
Highest pVL, log10 cp/mL 5.7 4.4 6.2
Total HIV-1 DNA, cp/106 CD4+ T cells
Before TD 3.8 25.42 111.0
After TD 199.1 46.1 1,356.7
Fold-change 52.4 1.8 12.2
Virologic control was defined as 2 consecutive pVL determinations of less than
200 copies/mL after cART initiation. The clinical classification of AIDS-defining
events and immunologic categories were based on international guidelines.
Prophylaxis with zidovudine, lamivudine, and nevirapine immediately fol-
lowed by cART was considered as initiation of cART.
Abbreviations: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; cART, combi-
nation antiretroviral therapy; CDC, Centers for Disease Control and Prevention;
ddI, didanosine; HIV-1, human immunodeficiency virus type 1; LPVr, ritonavir-
boosted lopinavir; ND, not determined; NVP, nevirapine; pVL, plasma viral load;
TD, treatment discontinuation.







VET (0–12 wk) ET (12–54 wk)
23 (100%) 14 (60.9%) 9 (39.1%)
Negative 4 (17.4) 4 (28.6) 0
.086Indeterminate 4 (17.4) 3 (21.4) 1 (11.1)
Positive 15 (65.2) 7 (50) 8 (88.9)
The result of the Inno-Lia HIV-1 I/II Score assay is shown as number (%). Data
were compared between infants initiating combination antiretroviral therapy
(cART) at <12 weeks of age (VET) and infants initiating cART between 12
and 54 weeks of age (ET) using the Fisher exact test.
Abbreviations: ET, early treatment; HIV-1, human immunodeficiency virus type
1; VET, very early treatment.
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of the case of the Mississippi baby [24]. Other cohorts of early-
treated childrenwith a very lowor undetectable proviral reservoir
have been established and proposed for treatment interruption
programs. Both absence of detectable HIV-1 DNA and absence
of low levels of replication-competent viruses in peripheral
blood were recently described in a subgroup of HIV-1-infected
children who initiated cART within 72 hours of birth, suggest-
ing that early cART could significantly reduce HIV reservoir
size [37]. However, definitive proof of functional cure can
only be established after long-term virologic control following
discontinuation of cART. Unfortunately, discontinuation in
early-treated infected children has invariably led to plasma
viral rebound [24, 38, 39]. Indeed, we also showed that despite
a small proviral reservoir in the peripheral blood of 3 of the chil-
dren in our study, plasma viraemia can rebound in only a few
days, leading to a marked increase in total HIV-1 DNA in CD4+
T cells (Figure 3A). Although we observed no correlations be-
tween serostatus and the time to viral rebound in the children
who stopped cART in our study, other immunological param-
eters, such as cytotoxic T lymphocyte responses or chronic
Figure 3. Reservoir size dynamics over time. A, Values of total human immunodeficiency virus type 1 (HIV-1) DNA from longitudinal samples are rep-
resented as mean ± standard error of the mean from patients who discontinued combination antiretroviral therapy (cART) (pink symbols) or did not dis-
continue cART (green symbols) after timepoint 0. The slope and P values were calculated using the linear mixed model. B, Longitudinal follow-up of Pt03.
Plasma viral load (green) and CD4+ T-cell count (dark grey) were measured from birth to 6 years of age. Total HIV-1 DNA levels (red) were measured in 4
samples, 1 of which was taken before the 3-week discontinuation of treatment (light grey line). After reinitiation of cART, reservoir size was measured
repeatedly over the following 3 years. Abbreviations: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; NVP, nevirapine.
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T-cell activation, could be relevant for remission of HIV and
warrant further study.
The origin of viral rebound is unclear. Although it could orig-
inate in peripheral blood cells, a large proportion of the viral
reservoir is actually located within the gut and other tissues
that are not accessed in most studies [40]. On the other hand,
replenishment of the reservoir might also become irreversible,
as depicted by the sustained level of total HIV-1 DNA in
Pt03 during the 3 years after discontinuation (Figure 3B).
Although it seems reasonable to think that the reservoir should
be as constrained as possible, we cannot conclude that a per-
sistent increase in reservoir size after interruption would neces-
sarily have long-term clinical consequences. Thus, before
analytical treatment interruptions could be performed safely
in vertically infected children, other reliable biomarkers to pre-
dict successful drug-free remission upon discontinuation need
to be validated.
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